Navigation Links
Amgen to Present at the Goldman Sachs Global Healthcare Conference
Date:6/8/2009

THOUSAND OAKS, Calif., June 8 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will present at the Goldman Sachs Global Healthcare Conference on Wednesday, June 10, 2009 at the Grand Hyatt, New York City, N.Y., beginning at 9:00 a.m. Eastern Time. Roger M. Perlmutter, Amgen's Executive Vice President of Research & Development, will present. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.

Information regarding presentation time, webcast availability, and webcast links are available on Amgen's Investor Relations Events Calendar.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

    CONTACT: Amgen, Thousand Oaks
    David Polk, 805-447-4613 (media)
    John Shutter, 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Loyola fellow receives Amgen grant to study treatments for older leukemia patients
2. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
3. Amgen Highlights Data to Be Presented at ASCO
4. Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
5. Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
6. Amgens First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
7. Amgen Announces Webcast of 2009 First Quarter Financial Results
8. Amgen to Present at the Barclays Capital Global Healthcare Conference
9. OmniPod(R) Insulin Management System Lets Team Type 1 Members Focus on Competing at Amgen Tour of California
10. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Colo. (May 21, 2013) Research into genetic features ... University of Colorado School of Medicine may lead to ... a paper published online by JAMA . , ... predict survival in some cases of pulmonary fibrosis, a ... years. As a result of the study, researchers may ...
(Date:5/21/2013)... May 21, 2013 The Las Vegas personal ... to announce that Crawford Gates, a senior at Coronado High ... college scholarship essay contest . As the winner of the ... essay contest started on Dec. 1, 2012 and ran through ... to submit a three-page minimum essay on “The Role of ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 While ... is synonymous with comprehensive travel guides. Brunswick Plantation & ... golf packages that include access to 27 holes of ... golf courses in North Carolina, knowing the Top ... and Lodges takes away the overwhelming task of selecting ...
(Date:5/21/2013)... Aggressive treatment for prostate cancer may not be ... conditions, a new study finds. Treatments for ... seed implants, can cause serious side effects, such ... explained researchers from the University of California, Los ... patients with slower growing forms of prostate cancer ...
(Date:5/21/2013)... as 35 percent of Mexican young adults may have ... Illinois scientist who conducted a study at the Universidad ... inherited genetic risk factors from both parents were already ... waist than those who hadn,t. They also had slightly ... of I professor of food science and human nutrition. ...
Breaking Medicine News(10 mins):Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2Health News:Genetic risk for obesity found in many Mexican young adults 2
... could lead to new birth control for men , WEDNESDAY, ... of proteins called PLA2s play a vital role in sperm ... , The findings could improve understanding of male infertility and ... for infertility. , In one study, Japanese researchers found that ...
... ... share the leading position in the European Union’s “Novel Foods” category , ... Provo, UT (Vocus) April 28, 2010 -- ... Commission on Food Safety. Now, not only do noni juice and noni leaf have Novel ...
... ... that more than 100 baby boys die from circumcision complications each year, including from ... deaths are avoidable. , ... (PRWEB) April 28, 2010 -- The International Coalition for Genital Integrity (ICGI) acknowledges ...
... ... elegant celebration of the unique bond between adults and their moms - has been released publicly ... ... A Poem for Mothers - I Honor You " by bestselling author Brian Vaszily has been ...
... ... Brooklyn Bridge Park playground is closed for renovation less than a month after opening. ... New York (PRWEB) April 28, ... down this week. Less than a month after it opened, the much-anticipated playground was declared ...
... ... Develop a 100 Percent Lead Free Bubbler Retrofit Kit , ... Los Angeles, CA (Vocus) April 28, 2010 -- Acorn ... and a division of Acorn Engineering Company, announces a 100 percent lead-free bubbler retrofit kit ...
Cached Medicine News:Health News:Third European Novel Food Approval Received by Tahitian Noni International 2Health News:Children's Rights Group Agrees with New Study: Infant Circumcision Causes 100 Deaths Each Year in US 2Health News:Inspirational Short Video for Adults Who Celebrate Their Mothers Called "A Poem for Mothers" Released on YouTube 2Health News:Inspirational Short Video for Adults Who Celebrate Their Mothers Called "A Poem for Mothers" Released on YouTube 3Health News:New York Personal Injury Lawyer, David Perecman, says New Playground is No Place for Kids 2Health News:New York Personal Injury Lawyer, David Perecman, says New Playground is No Place for Kids 3Health News:The Acorn Aqua's Lead Free Bubbler 2
(Date:5/21/2013)... , May 21, 2013  Janssen R&D ... results from the global Phase 3 PROMISE study ... simeprevir (TMC435) led to sustained virologic response 12 ... 79 percent of treatment-experienced genotype 1 chronic hepatitis ... all stages of liver fibrosis, when administered once ...
(Date:5/21/2013)... 21, 2013 Abaxis, Inc. (NasdaqGS: ABAX), a ... today that Martin Mulroy , chief ... Dental & Veterinary Conference on Wednesday, May 29, 2013 ... at Le Parker Meridien Hotel in New ... Abaxis develops, manufactures, markets and sells portable blood ...
(Date:5/21/2013)... -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: ... cell based therapies for various personal applications, announced that ... CEO, will be presenting at the Marcum MicroCap Conference.   ... Thursday, May 30, 2013 at the Grand Hyatt Hotel, ... City.  Mr. Weinreb,s presentation will take place at 2:30 ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
... Reported Consistent Pain-Free,Results From Attack to Attack, BOSTON, ... from,migraines frequently cite inconsistent effectiveness as a reason,for ... more,than 1,100 patients show that the investigational migraine ... two and,four hours, as well as a sustained ...
... 2, 2007 - Pluristem Life Systems,Inc. (OTCBB:PLRS), a ... for a variety of indications,announced today that it ... Meeting of the International Society for Cellular,Therapy (ICST), ... and Chairman, Mr. Zami Aberman commented, "We are,receiving ...
Cached Medicine Technology:Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across,Multiple Migraine Attacks 2Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across,Multiple Migraine Attacks 3Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across,Multiple Migraine Attacks 4Pluristem to Present Two Scientific Posters at the International,Society for Cellular Therapy 2Pluristem to Present Two Scientific Posters at the International,Society for Cellular Therapy 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: